582306-95-4Relevant academic research and scientific papers
One-step synthesis of aminopyrimidines from 5-oxo-4H-benzopyrans
Salfran, Esperanza,Suarez, Margarita,Verdecia, Yamila,Alvarez, Amaury,Ochoa, Estael,Martinez-Alvarez, Roberto,Seoaneb, Carlos,Martin, Nazario
, p. 509 - 516 (2004)
Novel 4-amino-6-aryl-2-phenylpyrimidine-5-carbonitriles have been prepared in one step procedure from the readily available 4-aryl-2-amino-3-cyano-5,6,7,8- tetrahydro-7,7-dimethyl-5-oxo-4H-benzopyrans. The mass spectroscopy study under EI conditions shows
Aminomethylpyrimidines as novel DPP-IV inhibitors: A 105-fold activity increase by optimization of aromatic substituents
Peters, Jens-Uwe,Weber, Silja,Kritter, Stephane,Weiss, Peter,Wallier, Angelina,Boehringer, Markus,Hennig, Michael,Kuhn, Bernd,Loeffler, Bernd-Michael
, p. 1491 - 1493 (2007/10/03)
The influence of aromatic substitution on a newly discovered class of inhibitors of dipeptidyl peptidase IV was investigated. A 105-fold increase in potency was achieved by the optimization of aromatic substituents in a parallel chemistry progr
Lead generation: Sowing the seeds for future success
Bleicher, Konrad H.,Nettekoven, Matthias,Peters, Jens-Uwe,Wyler, Rene
, p. 588 - 600 (2007/10/03)
Lead generation and the associated hit-to-lead process are key strategic elements in modern pharmaceutical research, and most companies have implemented this concept. Efficient lead generation is one of the main attempts to reduce the high attrition rates observed along the drug discovery process by focussing on the early developmental phases. The level of integration of the lead generation activities within the discovery organization, the flexibility in assessing and implementing new chemistries and new technologies, the high-quality standards set for the identification of the best possible chemical lead series will ultimately determine the future success in discovering new medicines.
Pyridine and pyrimidine derivatives
-
, (2008/06/13)
The present invention provides compounds of formula (I) wherein R1, R2, R3, R4 and X are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment
